All In Biotech

Drug Trial Radar · NCT07544628

A Phase 1 Study of Navlimetostat Tablet Formulations

A Phase 1, Open-label, Randomized, 2-Treatment, 2-Period, Crossover Study to Assess the Bioequivalence of Navlimetostat Wet-Granulation Tablet Versus the Dry-Granulation Tablet Formulation in Healthy Adult Female (as Assigned at Birth) Participants Who Are Individuals Not of Childbearing Potential

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Apr 27, 2026

Primary completion

Nov 2, 2026

Study completion Nov 2, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female

Conditions

  • Healthy Participants

Interventions

  • NavlimetostatDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax)Time frame: Up to Day 17
  2. Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]Time frame: Up to Day 17
  3. Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]Time frame: Up to Day 17
  4. Number of participants with Adverse Events (AE)Time frame: Up to approximately day 37
  5. Number of participants with Serious Adverse Events (AE)Time frame: Up to approximately day 37
  6. Number of participants with clinically significant changes in Physical Examinations (PE)Time frame: Up to Day 17
  7. Number of participants with clinically significant changes in vital signs (VS)Time frame: Up to Day 17
  8. Number of participants with clinically significant changes in 12-lead ECGsTime frame: Up to Day 17
  9. Number of participants with clinically significant changes in laboratory tests resultsTime frame: Up to Day 17

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel iResearch - Decatur

    Decatur, Georgia · Recruiting

  • Local Institution - 0003

    Decatur, Georgia · Withdrawn

  • Local Institution - 0001

    Austin, Texas · Withdrawn

  • Local Institution - 0004

    Austin, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.